CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Follow upWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug690 Current care per UCLA treating physicians Wiki 0.71
drug603 Colchicine Tablets Wiki 0.41
drug2067 Remdesivir Wiki 0.18

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D001927 Brain Diseases NIH 0.41
D016638 Critical Illness NIH 0.10
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001298 Encephalopathy HPO 0.41

There are 2 clinical trials

Clinical Trials

1 Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection

Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11, 2020. The infection affects all ages of life, although affecting children in a very small proportion of cases. The typical presentation of the disease combines fever (98%), cough (76%), myalgia and asthenia (18%) as well as leukopenia (25%) and lymphopenia (63%). Upper airway involvement rare. The main clinical presentation requiring hospitalization of infected patients is that of atypical pneumonia which may require critical care management (27%), and progress to an acute respiratory distress syndrome (67%) involving life-threatening conditions in almost 25% of patients diagnosed with SARS-CoV-2 infection. Other organ damage have been reported, mainly concerning kidney damage (29%) which may require renal replacement therapy in approximately 17% of patients. Neurological damage has been very rarely studied, yet reported in 36% of cases in a study including patients of varying severity. Finally, the mortality associated with this emerging virus is high in patients for whom critical care management is necessary, reported in 62% of patients. We therefore propose a prospective observational study which aim at reporting the prevalence of acute encephalopathy at initial management in Critical/Intensive care or Neurocritical care , to report its morbidity and mortality and to identify prognostic factors.

NCT04320472 COVID-19 Encephalopathy Critically Ill Other: Follow up
MeSH:Brain Diseases Critical Illness
HPO:Encephalopathy

Primary Outcomes

Description: ratio of patients with acute encephalopathy among the total of patients with SARS-Cov-2 infection at Critical/Intensive care or Neurocritical care admission

Measure: prevalence

Time: at Critical/Intensive care or Neurocritical care admission

Secondary Outcomes

Description: A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5. The Glasgow Outcome Scale (GOS) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]

Measure: Favorable outcome

Time: 3 months

Description: A favorable outcome is defined by a Glasgow Outcome Scale Extended (GOSe) >= 5. The Glasgow Outcome Scale Extended (GOSe) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor. The GOSe score : [1: Death, 2: Persistent vegetative state, 3: Severe disability Lower, 4: Severe disability Upper, 5: Moderate disability Lower, 6: Moderate disability Upper, 7 : Good recovery lower, 8 : Good recovery Upper]

Measure: Favorable outcome

Time: 3 months

2 Characteristics and Outcome of COVID-19 Among Egyptian Patients

The World Health Organization (WHO) has recently declared coronavirus disease 2019 (Covid-19) a public health emergency of international concern. Egypt is one of the countries that has been infected by Covid-19. The characteristics of clinical presentation, laboratory and radiological data are not yet studied. Outcomes of covid-19 in Egypt also have not been described yet.

NCT04339322 Characteristics Diseases Outcome, Fatal Other: Follow up

Primary Outcomes

Description: Sheet recording age, sex, co-morbidity,history of contact

Measure: Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group

Time: 2 months

Description: Sheet recording symptoms and signs

Measure: Clinical manifestations of Coronavirus Disease 2019 (COVID-19)

Time: 2 month

Description: blood picture,D-Dimer, creatinine, liver enzymes

Measure: Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort

Time: 2 months

Description: Chest x-ray and/or Computed tomography

Measure: Radiological features of Coronavirus Disease 2019 (COVID-19) cohort

Time: 2 month

Secondary Outcomes

Description: Data recording of the outcomes of treatment

Measure: outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group

Time: 1 week

Related HPO nodes (Using clinical trials)

HP:0001298: Encephalopathy
Genes 351
CHEK2 DNM1 ASNS KMT2E NDUFAF5 CHD2 GLUL SYNJ1 SUCLA2 ATP6V1A SCN3A AMACR RANBP2 SLC25A13 SLC13A5 COX1 SLC22A5 TSFM SCN8A ND2 ACTL6B RNASEH2C SLC6A9 NUS1 SPTAN1 CLP1 TRNF CNKSR2 NADK2 TREX1 PARS2 GABRB3 DPM2 ND3 SLC1A2 PCCB GRIN1 ARV1 ADAM22 CPLX1 ATP6V1A NDUFAF1 NDUFV2 BOLA3 GPR35 CHD2 SLC1A2 GCDH KCNT1 TRAK1 TRNC COG8 NEUROD2 SCN8A ATP1A3 HADH PNPT1 SYNJ1 HADH CDKL5 MEF2C COQ2 WWOX ACY1 DHDDS TRNK TRNL1 ND1 ND4 HNRNPU TRAK1 PPP3CA NDUFS3 TUFM CNPY3 BSCL2 NDUFV2 SCN1A ATP5F1A CAD HIBCH EEF1A2 SIK1 SERPINI1 CYC1 NTRK2 NAXD WDR45 TCF4 COX3 TRNQ KCNB1 GABRB1 FADD FADD HCN1 DENND5A SLC25A1 GABRA2 GBA NDUFB11 NDUFS1 GCSH PIGP ALG9 CACNA1A MDH2 NECAP1 DLD TBCD RNASEH2B NRXN1 CYTB PCCA TRNV LIPT2 CUX2 TIMMDC1 NDUFAF8 NDUFB10 CACNA1B HTRA1 WWOX TRAPPC12 COX3 TIMM50 NADK2 UNC80 SERAC1 COQ4 UGDH AP2M1 PIGA KCNQ2 SLC25A20 FCSK ATP5F1D MST1 PMPCB CUX2 NDUFS6 FOXRED1 GLDC NBAS SZT2 NDUFA11 XIAP KYNU TRNS2 ND1 CYFIP2 GALC NDUFS4 NDUFAF4 TRNQ DOCK7 MDM2 SLC19A3 TRNK PNPO CPT2 ACAD9 COQ9 AP3B2 EEF1A2 PNKP TRNS1 KCNB1 CYFIP2 TCF4 GRIN2D CLPB COG8 NDUFB3 SLC12A3 STAG1 STXBP1 TRNH NDUFS8 NAGS NDUFAF3 LIAS FGF12 NDUFAF4 TMEM126B NUS1 NDUFAF2 CACNA1A GLYCTK TBC1D24 MECP2 ETHE1 CCDC88A DNM1 SCN2A BSCL2 NTRK2 GABRG2 GRIN2D KCNQ2 DNM1 CPT1A CLCN4 COX2 TRNF RNF13 GBA GABRA1 TRNW GABRB2 GCDH SLC6A1 SLC2A1 SLC25A22 CLTC TGFB1 DGUOK PNPO ARHGEF9 GABRG2 ITPA ROGDI ATAD1 CLCNKB TK2 CACNA2D2 CACNA1E NECAP1 ZNHIT3 KCNQ5 NDUFA6 SZT2 NRXN1 NDUFA6 LYRM7 SLC25A15 NDUFS6 FBLN1 D2HGDH PRNP TBCE TMEM70 TSEN54 AARS1 STXBP1 IBA57 NDUFS3 UBA5 SUCLG1 NDUFS2 STAT2 NDUFV1 ARV1 TRNS2 GUF1 GNAO1 TBCK PACS2 PCK1 AP3B2 ACSF3 ATP5F1A CARS2 NDUFS4 YWHAG COX1 CDKN2A SH2D1A TWNK GLS TRNW CHD2 DNM1L ND5 NDUFA1 ARX PARS2 SLC25A15 NDUFA11 PLCB1 SLC19A3 MPC1 TBCE RANBP2 ND6 TP53 TH SLC35A1 KCNA2 ND5 CARS2 SLC22A5 HMGCL NDUFAF1 SYNGAP1 PPP3CA FBXL4 GABRB2 CNTNAP2 KCNT2 NDUFAF2 COX15 ARHGEF9 NAXE BCS1L ACY1 CACNA1B KYNU DLD TBC1D24 NDUFB3 GPT2 FRRS1L GRIN2B GABRB3 SCN1A TRNS1 NDUFB9 ST3GAL3 COX2 SLC25A22 FGF12 SLC13A5 DHDDS ACAD9 ETHE1 SLC35A2 PSAP GABRA5 UGT1A1 KCNA2 SCN1B MAPK10 UBA5 SIK1 KCNA2 HCN1 SLC25A12 SCN3A AMT ND6 NDUFS7 AARS1 TRNL1 SYNGAP1 NDUFS7 GABBR2 TRIT1 ND1 PHACTR1 NUBPL
Protein Mutations 1
A3243G
SNP 0